Good morning :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Medicamen Biotech Ltd

MEDICAMEQ

Medicamen Biotech Ltd

MEDICAMEQ
Health CarePharmaceuticals
SmallcapWith a market cap of ₹548 cr, stock is ranked 1,758
High RiskStock is 3.97x as volatile as Nifty
473.159.68% (+41.75)
473.159.68% (+41.75)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹548 cr, stock is ranked 1,758
High RiskStock is 3.97x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹548 cr, stock is ranked 1,758
High RiskStock is 3.97x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
74.932.650.23%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
49.716.310.52%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

MEDICAMEN Biotech is engaged in manufacturing of pharmaceutical formulations.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 7.54%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.06% to 0.05%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of -1.86%, vs industry avg of 15.28%

Loading...

Financial YearFY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue126.26127.44113.47117.17143.33181.64183.88
Raw Materialssubtract81.9580.4568.4255.6981.80104.70162.21
Power & Fuel Costsubtract2.112.902.685.865.677.14
Employee Costsubtract8.099.529.0014.5020.1529.07
Selling & Administrative Expensessubtract5.305.164.147.797.9014.95
Operating & Other expensessubtract7.698.008.807.511.00-0.07
Depreciation/Amortizationsubtract2.212.502.525.776.377.097.95
Interest & Other Itemssubtract1.380.931.511.943.395.674.29
Taxes & Other Itemssubtract5.504.694.273.202.202.142.11
EPS10.2811.119.9312.2011.948.635.76
DPS1.000.501.001.001.001.001.00
Payout ratio0.100.040.100.080.080.120.17
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF

Investor Presentation

Nov 13PDF
Aug 13PDF
Jun 30PDF
FY 2022

Annual report

PDF

Investor Presentation

Dec 4PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Medicamen Biotech Ltd50.092.650.23%
Sun Pharmaceutical Industries Ltd44.606.360.76%
Cipla Ltd28.724.420.89%
Torrent Pharmaceuticals Ltd63.3815.310.90%

Price Comparison

Compare MEDICAMEQ with any stock or ETF
Compare MEDICAMEQ with any stock or ETF
MEDICAMEQ
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding42.99%0.00%1.17%0.06%55.77%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.16%0.21%0.21%0.11%0.06%0.06%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividend Cuts

Dividends are the portion of earnings that a company distributes to all its shareholders every year

MEDICAMEQ has increased or maintained dividend levels over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.22%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.22 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 19, 2024

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 19, 2024

Cash Dividend

Ex DateEx DateSep 20, 2023

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 20, 2023

Cash Dividend

Ex DateEx DateSep 19, 2022

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 19, 2022

Cash Dividend

Ex DateEx DateSep 16, 2021

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 16, 2021

Cash Dividend

Ex DateEx DateSep 17, 2020

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Sep 17, 2020

News & Opinions
Earnings
Medicamen Biotech consolidated net profit declines 3.31% in the September 2024 quarter

Net profit of Medicamen Biotech declined 3.31% to Rs 1.46 crore in the quarter ended September 2024 as against Rs 1.51 crore during the previous quarter ended September 2023. Sales rose 2.76% to Rs 44.74 crore in the quarter ended September 2024 as against Rs 43.54 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales44.7443.54 3 OPM %11.8710.66 - PBDT4.564.29 6 PBT1.962.46 -20 NP1.461.51 -3 Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Medicamen Biotech declare Quarterly Result

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Medicamen Biotech to conduct AGM

Medicamen Biotech announced that the Annual General Meeting (AGM) of the company will be held on 26 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Medicamen Biotech to conduct board meeting

Medicamen Biotech will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live

Medicamen Biotech’s USFDA filing sparks 5.12 per cent surge in shares

1 year agoThe Hindu Businessline

Medicamen Biotech gains on successful ANDA filing for Bortezomib injections

1 year agoMoneycontrol

Medicamen Biotech announces debut in domestic pharma sector

2 years agoIndia Infoline

Aarvee Denims & Exports Ltd leads gainers in ‘B’ group

2 years agoBusiness Standard

Medicamen Biotech signs CDMO agreement with Vital Pharma Nordic

2 years agoBusiness Standard

Medi Caps gets approval under RERA for Real Estate Project ‘Medicaps Business Park’

2 years agoIndia Infoline